American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of maintenance rituximab following first-line systemic therapy on outcomes in patients with marginal zone lymphoma: Real-world evidence from 10 US Centers
    Meeting Abstract

    Epperla, N.; Annunzio, K.; Shouse, G. P.; Grover, N. S.; Torka, P.; Watkins, M. P.; Anampa-Guzmán, A. C.; Oh, T. S.; Reves, H.; Tavakkoli, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • HJKC3-0006: Outcome of patients with CML treated on second line or later therapy in routine clinical practice
    Meeting Abstract

    Thompson, J. E.; Gao, Y.; Visotcky, A.; Flynn, K. E.; Mauro, M.; Giever, E.; Baim, A.; Akinola, I.; Larson, R.; Jamy, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world tisagenlecleucel outcomes in Richter-transformed chronic lymphocytic leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) analysis
    Meeting Abstract

    Shadman, M.; Frigault, M. J.; Foley, S. R.; Hill, B. T.; Schofield, G.; Jacobson, C.; Jaglowski, S. M.; Locke, F. L.; Landsburg, D. J.; Ram, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Analysis of cytopenias and infections in pts from KarMMa-3
    Meeting Abstract

    Baz, R.; Otero, P. R.; Ailawadhi, S.; Arnulf, B.; Patel, K. K.; Nooka, A. K.; Costa, L.; Raje, N. S.; Abrahamsen, I. W.; Delforge, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Chimeric antigen receptor T-cell (CAR-T) therapy in secondary central nervous system large B-cell lymphoma (SCNSL): A multicenter retrospective analysis
    Meeting Abstract

    Ahmed, G.; Alsouqi, A.; Szabo, A.; Rojek, A. E.; Riedell, P. A.; Awan, F. T.; Samples, L.; Shadman, M.; Hu, M.; Bachanova, V.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Preliminary safety, pharmacokinetics, pharmacodynamics and clinical activity of KT-333, a targeted protein degrader of STAT3, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors
    Meeting Abstract

    Shastri, A.; Feldman, E. J.; Starodub, A. N.; Feldman, T.; Rodriguez, C. P.; Epstein-Peterson, Z. D.; Stevens, D. A.; Olszewski, A. J.; Huen, A. O.; Porcu, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Durable efficacy and manageable safety in patients age≥75 years with relapsed/refractory large B-cell lymphoma treated with tisagenlecleucel in the real-world setting
    Meeting Abstract

    Landsburg, D. J.; Heim, M.; Moskop, A.; Foley, S. R.; Hill, B. T.; Schofield, G.; Jacobson, C.; Jaglowski, S. M.; Locke, F. L.; Ram, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • HJKC3-007: Outcomes of patients with chronic myeloid leukemia in chronic phase treated with asciminib and other tyrosine kinase inhibitors in routine clinical practice
    Meeting Abstract

    Mauro, M.; Atallah, E. L.; Thompson, J. E.; Gao, Y.; Visotcky, A.; Giever, E.; Baim, A.; Akinola, I.; Larson, R. A.; Jamy, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1a/b trial of luxeptinib (CG-806) in patients with relapsed/refractory B-cell malignancies or acute myeloid leukemia and evaluation of new G3 formulation
    Meeting Abstract

    Goldberg, A. D.; Samaniego, F.; Ohanian, M.; Koller, P. B.; Chandhok, N. S.; Sadiq, A. A.; Mahadevan, D.; Cherry, M. A.; Altman, J. K.; Burke, J. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) among patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving pirtobrutinib: Analysis from the BRUIN phase 1/2 study
    Meeting Abstract

    Coombs, C. C.; Woyach, J. A.; Brown, J. R.; Ghia, P.; Roeker, L. E.; Patel, K.; Eyre, T. A.; Tam, C. S.; Seymour, J. F.; Shah, N. N.; more...
    Blood (2023)

    Fulltext@MSK | Save